MetaCap

Mineralys Therapeutics (MLYS) vs MannKind (MNKD)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

MannKind (MNKD) has outperformed Mineralys Therapeutics (MLYS) over the past year, losing 23.5% versus a loss of 67.4%. MannKind is the larger company by market cap ($1.24 billion vs $1.21 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MLYS-67.38%MNKD-23.46%
+28%-22%-72%
Nov 21, 20251 yearNov 20, 2026
MLYS-25.92%MNKD-25.39%
+146%+35%-76%
Feb 6, 20235 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MLYS versus MNKD key metrics
MetricMLYSMNKD
Share price$13.66$3.85
Market cap$1.21B$1.24B
1-day change-3.53%-2.53%
YTD return-62.36%-32.10%
1-year return-67.38%-23.46%
5-year return—-16.85%
Forward P/E—24.44
EPS (TTM)$-4.30$-0.24
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$348.97M
Revenue growth (YoY)—+22.23%
Net income (latest FY)$-154.65M$5.86M
Gross margin—92.32%
Operating margin—11.12%
Net margin—1.68%
52-week high$44.13$6.51
52-week low$13.57$2.23
Distance from 52-week high-69.05%-40.86%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+218.89%+116.36%
Average volume1.55M3.96M
Shares outstanding88.56M321.64M
Employees76591
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • MNKD has outperformed MLYS by 43.9 percentage points over the past year.

About Mineralys Therapeutics

MLYS stock →

Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea.

Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees

About MannKind

MNKD stock →

MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address various unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 591 employees

MLYS vs MNKD FAQ

Which is bigger, Mineralys Therapeutics or MannKind?

MannKind (MNKD) is larger, with a market capitalization of $1.24B compared with $1.21B for Mineralys Therapeutics (MLYS).

Which stock has performed better over the past year, MLYS or MNKD?

MNKD returned -23.46% over the past 12 months, compared with -67.38% for MLYS (price return, excluding dividends). Past performance does not predict future results.

Are Mineralys Therapeutics and MannKind in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons